Xtandi FDA Approval History
Last updated by Judith Stewart, BPharm on May 4, 2021.
FDA Approved: Yes (First approved August 31, 2012)
Brand name: Xtandi
Generic name: enzalutamide
Dosage form: Capsules and Tablets
Company: Astellas Pharma US, Inc.
Treatment for: Prostate Cancer
Xtandi (enzalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer.
Development timeline for Xtandi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.